The key miRNA Biomarker panel of pancreatic ducal adenocarcinoma

The key miRNA Biomarker panel of pancreatic ducal adenocarcinoma
Mahsa Mousakhan Bakhtiari,^1,* Romina Seifollahi Asl,² Mohammadamin Mahmanzar,³
1. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Bioinformatics and Computational Omics Lab (BioCOOL), Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
Introduction: Cancer is one of the most destructive diseases Gastrointestinal (GI) cancers are among the most prevalent and lethal tumor globally. Statistics showed that each year, of the 18 million diagnosed universally, about 500,000 cases were pancreatic. Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent type. It is considered as the fourth leading cause of cancer death. The poor specificity and sensitivity of PDAC’s biomarkers in conventional clinical purposes seems to be one of the major obstacles in this illness MicroRNAs (miRNAs), considered to regulate the activity of approximately 30% of all protein-coding genes in mammals aberrant expression of miRNAs as the small non-coding RNAs have been identified as a potential appliance for early diagnosis, prediction of treatment response, and prognosis of patients with PDAC. In this study, we aimed to collect all microarray data which is related PDAC gene expression and drawing protein-protein interaction networks to found the correlation of final genes Moreover, pathway analysis was performed to clarify much more important biological pathways in PDAC develops
Methods: datasets of pancreatic ductal adenocarcinoma were searched using the keywords: ‘pancreatic ductal adenocarcinoma, ‘Homo sapiens’ and ‘Expression profiling by array’ against the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo). To identify differentially expressed miRNA, each dataset was analyzed by limma R package in Bio conductor. Significant differential expression was determined as a log fold change ≥ |2| and adjusted p-value threshold of 0.001. To find the hub target genes, draw gene-miRNA Interaction network and report the hub targeted genes
Results: After a systematic review, 4 GSE profiles from 9 datasets (GSE109918 , GSE101094, GSE89139, GSE41369) which totally include 47 cases, were included. To the evaluated quality of data. Heat map and principle Component Analysis (PCA) was performed. Based on logFC and target genes which were summarized in table. As Up-regulated candidates miR-155, miR-221, miR-222 and miR-126, miR-193b, miR-106b as down-regulated miRNA, respectively
Conclusion: About the poor prognosis of pancreatic cancer in human societies, understanding the events and molecular pathways, as well as taking early health strategies with an emphasis on biological markers is very important. Recent researches on epigenetic mechanisms have shown that regulatory features are involved in the development, progression, and metastasis of pancreatic cancer. For example, the mir-1290 has a dedicated function and is a good alternative to the CA19-9 marker. This biomarker is very important for screening people who have a family history of pancreatic cancer. Also, mir-373 is very effective in the process of metastatic pancreatic cancer
Keywords: pancreatic ductal adenocarcinoma, miRNA expression, Bioinformatics,